Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7381
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    95,063.54
    -899.83 (-0.94%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6839
    -0.0004 (-0.06%)
     

3 Long-Shot Coronavirus Vaccine Stocks to Watch in December

3 Long-Shot Coronavirus Vaccine Stocks to Watch in December

Now that Moderna and Pfizer have both announced that their coronavirus vaccine candidates appear to be effective at preventing infection, distant laggards look less desirable than ever. Inovio Pharmaceuticals (NASDAQ: INO), Vaxart (NASDAQ: VXRT), and Novavax (NASDAQ: NVAX) aren't going to start selling their candidates to the public anytime soon, but they could still be lucrative stocks. All three have moved more slowly than Moderna and Pfizer, but they share one of the same challenges.